I'm LongbridgeAI, I can summarize articles.Barclays maintained Viatris at Overweight and raised its price target to $25 from $22, a 13.6% increase.
The price target implies an upside of 20.1% from the Nov 13 close of $20.82.
Explore more price target data and ratings for Viatris on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
